MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma by Ferrer, Irene et al.
RESEARCH Open Access
MAP17 predicts sensitivity to platinum-
based therapy, EGFR inhibitors and the
proteasome inhibitor bortezomib in lung
adenocarcinoma
Irene Ferrer1,2, Álvaro Quintanal-Villalonga1,7, Sonia Molina-Pinelo3, Jose Manuel Garcia-Heredia2,3,4, Marco Perez2,3,
Rocío Suárez1, Santiago Ponce-Aix1,5, Luis Paz-Ares1,5,6 and Amancio Carnero2,3*
Abstract
Background: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification
both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to
increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a
common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression.
Methods: We assessed the expression of MAP17 in preclinical models, including cell lines and patient-derived xenografts
(PDXs), assessing its correlation with sensitivity to different standard-of-care drugs in lung adenocarcinoma, as well as
novel drugs. At the clinical level, we subsequently correlated MAP17 expression in human tumours with patient response
to these therapies.
Results: We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas,
and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in
adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. In addition, we show that MAP17
expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a
novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas.
Conclusions: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung
adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based
therapy and EGFR inhibitor efficacy. Furthermore, we propose bortezomib treatment as a novel and efficacious therapy
for lung adenocarcinomas exhibiting high MAP17 expression.
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Background
Pulmonary tumours are a major health problem due to
both their high incidence and mortality and are respon-
sible for the majority of cancer-related deaths [1]. Lung
cancer is a heterogeneous entity that is classified into
two major histologically distinct groups: small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC).
Within NSCLC, different histological subtypes can be
further distinguished: large cell carcinoma (LCC), squa-
mous cell carcinoma (SCC), and adenocarcinoma
(ADC). ADC is the most prevalent subtype, comprising
approximately 50% of all lung cancer cases [2]. The
overwhelmingly poor prognosis of patients with lung
cancer, with an expected 5-year survival rate of only
18%, is a consequence of both late diagnosis and the
relative lack of effective systemic treatments [3]. Rela-
tively recent clinical implementation of a limited number
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of targeted therapies, such as EGFR and ALK inhibitors,
has shown benefit in select patients [4], and recently ap-
proved immunotherapies have shown very promising re-
sults [5]. However, the gold-standard therapy for most
lung cancer patients remains classical chemotherapy,
with special emphasis on platinum-based compounds.
Thus, the identification of biomarkers predicting efficacy
for therapies in use is crucial to improve patient survival
in this setting. Furthermore, new therapies are necessary
to cover the spectrum of patients for whom currently
available treatments are insufficient.
MAP17 (DD96, PDZKIP1) is a small, nonglycosylated
membrane-associated protein of 17 kDa located in the
plasma membrane and the Golgi apparatus [6], which ex-
erts pro-tumourigenic effects in tumour cells by increas-
ing levels of reactive oxygen species (ROS) [7, 8]. MAP17
overexpression has been observed in a wide variety of hu-
man carcinomas [9], including cervical, breast, prostate,
and ovarian tumours, where expression of this gene is
strongly correlated with tumour progression [9, 10]. Ele-
vated MAP17 levels have been associated with good re-
sponse to platinum-based compounds in cervical and
laryngeal carcinomas [10, 11] and with increased sensitiv-
ity to bortezomib (Velcade, PS-341), a proteasome inhibi-
tor approved for the treatment of multiple myeloma and
mantle cell lymphoma [12, 13] as well as breast tumours
and sarcomas [7, 14, 15]. Therefore, we hypothesize that
MAP17 may prove useful for stratifying patients with re-
spect to current or new lung adenocarcinoma therapies.
In the present study, we explored the relevance of
MAP17 expression in lung malignancies and its poten-
tial role as a predictive biomarker for currently used sys-
temic therapies in the most prevalent lung cancer
histological subtype, adenocarcinoma.
Methods
Study approval
Written informed consent was provided by all patients.
This project was approved by the Research Ethics Com-
mittee of the Hospital Universitario 12 Octubre (Madrid,
Spain) (CEI 16/297).
All procedures involving animals were approved by
the Consejería de Agricultura y Pesca of the Junta de
Andalucía (Approval ref.: SSA/SI/MD/pdm) and by Ani-
mal Protection of the Comunidad Autónoma de Madrid
(Approval ID: PROEX134/16).
Clinical samples
The present study utilized different NSCLC patient co-
horts. The first cohort comprised 248 subjects diagnosed
with NSCLC (Additional file 1: Table S1) from the Vir-
gen del Rocio University Hospital (Seville, Spain) who
had undergone surgical resection. Tumour samples were
sent to the pathology laboratory for diagnosis and were
prepared for storage by formalin fixation and paraffin
embedding. Samples were haematoxylin/eosin-stained,
and tumoural tissue was selected and included in TMAs
by a pathologist to perform immunohistochemistry
(IHC). The inclusion criteria were as follows: (1) con-
firmed NSCLC diagnosis; (2) access to patient clinical
information, including age, sex, smoking status, TNM
stage, diagnosis date, histologic subtype, date of relapse,
date of the last revision and status at that time; and (3)
availability of tumour tissue obtained by surgical resec-
tion for immunohistochemistry.
A second independent cohort containing 40 DNA sam-
ples from patients diagnosed with NSCLC from the Vir-
gen del Rocio University Hospital (Seville, Spain) who had
undergone surgical resection was also utilized. These sam-
ples were composed of 20 matched tumour and
non-tumour samples, each from the same patient. Clinical
features of patients with NSCLC for this cohort are sum-
marized in Additional file 1: Table S2 [17]. The majority of
samples were obtained from patients following surgical re-
section for clinical early-stage NSCLC, but ten samples in-
cluded stages III and IV disease. A description of this
cohort can also be found in the literature [18]. During the
surgical procedure, the tumour and matched non-tumour
tissue samples were collected from patients and immedi-
ately snap-frozen at − 80 °C for future use.
A third independent cohort involved 42 subjects diag-
nosed with advanced (stage III-IV) adenocarcinoma
from the University Hospital 12 de Octubre (Madrid,
Spain) given erlotinib or gefitinib as first- or
subsequent-line treatment. Tumour samples were sent
to a pathology laboratory for diagnosis and prepared for
storage by formalin fixation/paraffin embedding. The in-
clusion criteria were as follows: (1) confirmed NSCLC
diagnosis; (2) access to patient clinical information; and
(3) availability of tumour tissue obtained by surgical re-
section. Baseline characteristics of patient cohorts are
summarized in Additional file 1: Table S3.
For the tumour marker prognostic study, the RE-
MARK [18] reporting guidelines were followed.
Public databases of clinical samples
To validate our results, we obtained data from publicly
available clinical and genomic information from Onco-
mine (https://powertools.oncomine.com) and TCGA Re-
search Network (http://cancergenome.nih.gov/).
Cell lines
Twelve lung adenocarcinoma cell lines (A549, H460,
H2009, H358, H1650, H1975, HCC827, H2228, H3122,
H1437, H1781 and Calu-3), four lung squamous cell car-
cinoma cell lines (Calu-1, HTB59, H520 and H226) and
two immortalized lung epithelial cell lines (NuLi-1 and
NL-20) were used (Additional file 1: Table S4) for in
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vitro studies. All cell lines were purchased from ATCC im-
mediately before beginning this work, with the exception
of H3122, which was kindly provided by Dr. Maina. All cell
lines were cultured according to ATCC or donor guide-
lines. All cell lines were regularly tested for mycoplasma.
Immunohistochemistry
Tumoural area from the samples was identified by pa-
thologists following haematoxylin-eosin staining [19, 32].
Tissue microarrays (TMAs) were constructed from the
preselected tumoural area from every biopsy. Tissue pro-
cessing was performed while protecting samples from
oxidation and maintaining the integrity of each sample
during the process. De-paraffinization and antigenic epi-
tope recovery was performed using the PTLinK kit
(Dako). Immune detection was performed with MAP17
as described [11, 20].
Illumina 450 K methylation and data processing
The Illumina Infinium Human Methylation 450 BeadChip
(Illumina Inc., San Diego, CA, USA) was used to interro-
gate 485,000 methylation sites per sample across the gen-
ome at single-nucleotide resolution. We treated 500 ng of
DNA with sodium bisulphate using the EZ DNA Methyla-
tion™ Kit and cleaned the DNA with the ZR-96 DNA
Cleanup Kit™ (EZ DNA, Zymo Research, Irvine, CA, USA)
before standard Illumina amplification, hybridization, and
imaging. The resulting intensity files were analysed with
Illumina’s GenomeStudio, which generated β-scores.
Methylome data were processed as in [17, 20].
Transfections
Using TransIT-X2 (Mirus), cell lines were transfected
with MAP17 overexpression or downregulation plasmids
reported in [15, 20, 21].
Patient-derived xenografts (PDXs) and in vivo treatments
We used a collection of NSCLC PDX models established
at the Institute of Biomedicine in Seville (IBIS). Resected
lung tumours from HUVR (Hospital Universitario Virgen
del Rocío, Sevilla, Spain) patients were obtained from the
Biobank of this hospital and subcutaneously inoculated
and expanded in successive groups of nude mice to gener-
ate a bank for each tumour. For this study, PDXs were se-
lected based on histology, genetic background and
MAP17 expression. Tumours were cut into 50–100 mm3
pieces and inserted subcutaneously into one flank of the
mouse. Four to eight mice were included in each group.
Tumours were measured twice a week, and when tumour
volume reached 150 mm3, mice were randomized into
different control and treatment groups. Mice were sacri-
ficed at the end of treatment (after 5 weeks), and tumours
were harvested. Carboplatin was intraperitoneally admin-
istered twice a week at 25 mg/kg/day. Erlotinib was
administered five times a week, at 50 mg/kg/day by oral
gavage. Bortezomib was administered 5 times a week, at
1 mg/kg/day as in [16]. Mice were monitored daily for
signs of distress and were weighed twice a week. Tumour
size was determined using callipers according to the fol-
lowing equation: tumour volume = [length Å~ width2]/2.
The duration of treatment was 5 weeks, unless rapid
tumour growth necessitated an earlier endpoint. In these
experiments, blinding was achieved by having one person
treat the animals and a different person measure the tu-
mours and process data. All the procedures involving ani-
mals were approved by the Consejería de Agricultura y
Pesca of the Junta de Andalucía (Approval ref.: SSA/SI/
MD/pdm) and by Animal Protection of the Comunidad
Autónoma de Madrid (Approval ID: PROEX134/16).
Immunoblotting
Protein was extracted using RIPA buffer (Sigma) with a
protease inhibitor cocktail (cOmplete Mini EDTA-free,
Roche) and a phosphatase inhibitor cocktail (PhosSTOP
EASYpack, Roche) [21]. We used the following primary
antibodies: anti–NFKB-p65 (1:2000; Abcam #ab16502),
anti–NFKB-p65 (phospho-Ser536) [93H1] (1:1000; Cell Sig-
naling Technology #3033), anti-IKKa [Y463] (1:5000;
Abcam #ab32041), anti-IKKa (phospho-Ser32/36) [5A5]
(1:1000; Cell Signaling Technology #9246), anti-p44/4S2
MAPK [137F5] (1:2000; Cell Signaling Technology #4695),
anti-p44/42 MAPK (phospho-Thr202/Tyr204) [E10]
(1:2000; Cell Signaling Technology #9106), anti-LC3B
(1 mg/mL; Abcam #ab48394), EGFR (#4267, CST), pEGFR
(#2234, CST) and β-actin (#A5316, Sigma). β-actin protein
expression was used as a loading control. Horseradish
peroxidase-conjugated secondary antibodies were used for
chemiluminescence-based detection of protein expression
in the ChemiDoc detection system (BioRad).
Cell line treatments
The inhibitory concentration 50 (IC50) was calculated as
in [22]. For cell line treatments, cells were treated with
their IC50 and 2X IC50 concentration for 24 h, and pro-
tein was subsequently extracted.
RNA extraction and analysis
RNA was extracted from cell lines using Trizol reagent
(Life Technologies) [9]. RNA extraction of
paraffin-embedded patient and PDX tumour tissue was
performed with the RecoverAll Extraction Kit (Life
Technologies, #AM1975). RNA samples were reverse
transcribed using the TaqMan Reverse Transcription Kit
(Life Technologies). Gene expression analysis was per-
formed using TaqMan probes from Life Technologies:
Hs00906696_m1 FAM (PDZK1IP) and Hs99999905_m1
FAM (GAPDH). GAPDH was used as a reference gene
to normalize expression data.
Ferrer et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:195 Page 3 of 13
Public database of cancer cell line sensitivity to drugs
Information on sensitivity to different chemotherapeutic
agents, targeted therapies, and MAP17 mRNA expres-
sion was obtained from the Genomics of Drug Sensitiv-
ity in Cancer (GDSC) [23].
Statistical methods
In vitro data are represented as the mean ± standard de-
viation. Statistical analysis was performed with the SPSS
statistical package (v19, IBM). In vitro and in vivo exper-
iments were analysed using an unpaired non-parametric
Mann-Whitney’s U or Student’s t tests. p-values less
than 0.05 were considered significant. The Kaplan-Meier
method was used for survival analyses of clinical data
and cell line xenograft experiments, with a Cox propor-
tional hazards model to adjust for explanatory variables.
Overall survival (OS) was defined as the length of time
from the date of diagnosis to the date of the last medical
record. Progression-free survival (PFS) was defined as
the length of time from the date of diagnosis to the date
of relapse. A type II ANOVA was used to analyse differ-
ences in survival among groups. To obtain hazard ratio
values, the Cox proportional hazards model was used.
Results
MAP17 Upregulation is a common feature of lung
tumours and is preferentially detected in lung
adenocarcinoma
To assess MAP17 expression in the context of lung can-
cer, we determined MAP17 protein levels in both
non-tumour lung tissue and NSCLC samples by immu-
nohistochemistry (Additional file 1: Table S1). We de-
tected increased MAP17 protein expression in tumour
samples compared to that in normal lung samples
(Fig. 1a). To confirm this result, we examined MAP17
mRNA expression in a TCGA lung cancer patient cohort
and observed that this gene is overexpressed in adeno-
carcinoma and squamous cell carcinoma samples com-
pared to that in normal lung tissue (p < 0.001 and p <
0.001, respectively), with adenocarcinomas exhibiting the
highest expression levels, superior to even those found
in squamous cell carcinoma tumours (p < 0.001, Fig. 1a).
These results were further validated in independent co-
horts from the publicly available data repository Onco-
mine (Additional file 1: Figure S1B-D). In addition,
MAP17 mRNA levels were determined in a set of
non-tumour lung epithelial, adenocarcinoma and squa-
mous cell lung carcinoma cell lines (Additional file 1:
Table S4), and similar results were obtained, with adeno-
carcinoma cell lines exhibiting the highest MAP17 ex-
pression levels, followed by squamous cell carcinoma
cell lines and non-tumoural cell lines, which showed
minimal MAP17 expression (Additional file 1: Figure
S1E). Next, to further characterize these results, the
methylation profile of MAP17 was evaluated in human
lung tumours and compared to that in matched
non-tumoural tissues from a cohort of NSCLC patients
(Additional file 1: Table S2) using the Illumina Infinium
Human Methylation 450 BeadChip. Lung cancer tissue
exhibited deregulated MAP17, with lower methylation
that was statistically significant in the promoter region
(p = 0.003). In addition, we identified more notable dif-
ferences in hypomethylation status at promoter regions
in squamous cell carcinoma compared to that in adeno-
carcinoma (p = 0.014 and p = 0.050, respectively). There-
fore, we detected decreased methylation levels in
tumour samples in both adenocarcinoma and squamous
cell carcinoma (Fig. 1c), suggesting that MAP17 overex-
pression in lung cancer may be a consequence of gene
demethylation events.
MAP17 Expression as a prognostic determinant in NSCLC
As MAP17 overexpression was observed in NSCLC sam-
ples, we decided to assess whether its expression corre-
lates with clinical characteristics in different public
transcriptomic datasets (Lung Metabase (six validated co-
horts), n = 1053, (SurvExpress compilation) and Directors
Challenge Consortium NCI lung, n = 453, PMID:
18641660). In the Lung Metabase formed by 6 cohorts (n
= 1053), we observed that high levels of MAP17 mRNA
correlate to high risk for tumours and trend to poor prog-
nosis in total lung tumours (Fig. 2a). Similar data were ob-
served in the lung tumour cohort from Directors
Challenge Consortium (n = 462) (Fig. 2b). When the
former cohort of 1056 tumours was subdivided according
to histology, we still observed a clear trend for worse
prognosis in both common types of tumours, ADC and
SCC (Fig. 2c). Furthermore, this trend for worse prognosis
was independent of stage (Additional file 1: Figure S2).
Interestingly, when the individuals were separated by
radiation treatment, the individuals with increased levels
of MAP17 still showed worse prognosis (Fig. 2d), indi-
cating the relevance of the determination of this marker
in the response.
Overall, taken together, the data suggest that high
MAP17 levels showed worse prognosis than did patients
with tumours with low MAP17 levels, and this is inde-
pendent of histology and stage and radiation treatment.
Therefore, we explored whether MAP17 can be a marker
for specific chemotherapy responses and whether we can
improve them.
MAP17 Expression is predictive for platinum-based
therapy sensitivity in lung adenocarcinoma
As MAP17 expression was highest in adenocarcinoma
(Additional file 1: Figure S1), which is the lung tumour
subtype with the highest prevalence, we decided to focus
our work on this histological subtype. As MAP17 has
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been correlated with platinum-based compounds
through ROS induction in other tumour types [10, 11],
we evaluated sensitivity to cisplatin and carboplatin, the
gold-standard therapy in most of the advanced lung can-
cer cases, in a panel of 13 adenocarcinoma cell lines
(Additional file 1: Table S5). To this aim, we determined
the drug concentration inhibiting 50% of cell growth
(IC50) and correlated these data with MAP17 mRNA
levels. We observed a clear trend showing that cell lines
with high MAP17 expression were more sensitive to cis-
platin (p = 0.18) and a statistically significant association
of higher MAP17 levels and carboplatin sensitivity (p =
0.01, Fig. 3a). Furthermore, we confirmed these results
for cisplatin by analysing publicly available data from the
Genomics of Drug Sensitivity in Cancer (GDSC) data-
base. We found the same trend in the database, suggest-
ing that adenocarcinoma cell lines with high MAP17
expression are more sensitive to this compound (p =
0.09, Fig. 3b). In addition, we overexpressed MAP17 in
the adenocarcinoma cell line H1975, which normally ex-
presses low levels of MAP17, and silenced expression of
this gene in the Calu3 line, which normally expresses
high levels of MAP17. We then assessed the sensitivity
of these cell lines to the platinum compounds. We ob-
served higher sensitivity to both drugs in cell lines with
high levels of MAP17 and low sensitivity to the drugs in
cells with low levels of MAP17 (Fig. 3c), further support-
ing our previous results.
Fig. 1 MAP17 upregulation occurs during lung tumourigenesis and is preferentially detected in lung adenocarcinomas. a Representative images
of MAP17-stained lung tumour samples. b MAP17 mRNA expression in non-tumour (Normal), adenocarcinoma (ADC) and squamous cell
carcinoma (SCC) samples from the TCGA Lung Cancer cohort. c MAP17 promoter and gene methylation in non-tumour and NSCLC samples (See
Additional file 1: Table S2). Observed methylation changes (log2 ratio). Statistically significant differences (adjusted p-value < 0.05) of methylation
levels with respect to those of the control (non-tumour) group were considered. The upper schematic represents the main location of probes for
promoter or gene analysis. Below are comparative values of expression
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To assess the in vivo relevance of these findings, we
assessed MAP17 mRNA expression in four lung adeno-
carcinoma PDXs (Fig. 3d) and treated them with carbo-
platin. We observed that the two models exhibiting low
MAP17expression, TP40 and TP60, were insensitive to
carboplatin treatment, while those models with the high-
est MAP17 expression, TP57 and TP79, were sensitive
to the drug, with tumour growth inhibition (TGI)
percentages of 49.5% and 66.4%, respectively (Fig. 3e).
Finally, to assess the predictive potential of MAP17
expression for platinum-based therapy response, we ana-
lysed survival of a subset of patients from the TCGA
adenocarcinoma cohort treated with cisplatin and/or carbo-
platin. We found that patients with high MAP17expression
exhibited higher overall survival when analysing cisplatin/
carboplatin-, cisplatin- and carboplatin-treated subsets (p =
0.002, p = 0.015 and p = 0.051, respectively, Fig. 3f).
MAP17 Expression predicts response to EGFR inhibitors in
lung adenocarcinoma
As EGFR inhibitors have been associated with ROS induc-
tion, similar to platinum-based compounds [24], we
assessed the predictive potential of MAP17expression for
erlotinib sensitivity in vitro. To this aim, we determined
Fig. 2 Prognostic analysis of MAP17 expression in NSCLC. a Analysis of the risk (left) and survival probability (right) based on MAP17 expression in
lung cancer tumours from the Lung Metabase [38]. Red: high risk; Green: low risk. b Analysis of the risk (left) and survival probability (right) based
on MAP17 expression in lung cancer tumours from the NCI directors challenge consortium database [39]. Red: high risk; Green: low risk. c Analysis
of survival probability based on MAP17 expression in adenocarcinoma or squamous carcinoma lung cancer tumours from the Lung Metabase
database. D) Analysis of survival probability based on adjuvant radiotherapy treatment based on MAP17 expression in lung cancer tumours from
the Lung Metabase database (n = 1053)
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erlotinib IC50 in our adenocarcinoma cell line panel and
compared those results to the MAP17 levels (Additional
file 1: Tables S4 and S5). We found that cell lines with the
highest MAP17 expression showed increased erlotinib
sensitivity compared to that of the other the cell lines (p =
0.01, Fig. 4a). In addition, we determined erlotinib
Fig. 3 MAP17 expression predicts platin sensitivity in lung adenocarcinoma. a Correlation of cisplatin (up) and carboplatin (down) sensitivity in
lung adenocarcinoma cell lines based on MAP17 expression. b Correlation of cisplatin sensitivity in adenocarcinoma cell lines based on MAP17
expression, with data obtained from the GDSC database. c Cisplatin (up) and carboplatin (down) sensitivity in MAP17-overexpressing and MAP17-
silenced lung adenocarcinoma cell lines. d Determination of MAP17 mRNA expression in lung adenocarcinoma PDXs. e Tumour growth
assessment of carboplatin-treated adenocarcinoma PDXs with differential MAP17 expression. f Kaplan-Meier overall survival curves for lung
adenocarcinoma patients from the TCGA database (Additional file 1: Table S6) treated with cisplatin, carboplatin, or both. Patients were divided
based on MAP17 expression levels into two groups, below or above the 75th percentile of expression
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Fig. 4 MAP17 expression predicts sensitivity to erlotinib in lung adenocarcinoma. a Erlotinib sensitivity in lung adenocarcinoma cell lines based
on MAP17 mRNA expression. b Erlotinib sensitivity in one MAP17-overexpressing and one MAP17-silenced lung adenocarcinoma cell lines. c
Analysis of sensitivity to different EGFR inhibitors in lung adenocarcinoma cell lines based on MAP17 expression using data from the GDSC
database. Determination of MAP17 expression (d) and EGFR activation (e) in lung adenocarcinoma PDXs. (F) Tumour growth assessment in
erlotinib-treated adenocarcinoma PDXs with differential MAP17 expression. g Response to erlotinib or gefitinib treatment in adenocarcinoma
patients (Additional file 1: Table S3) with tumours harbouring low or high MAP17 mRNA expression. Expression was considered as high with
values above the median value (left) or the 75th percentile (right)
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sensitivity in MAP17-overexpressing H1975 and MAP17-
silenced Calu-3 cell lines and found a trend suggesting
that MAP17 overexpression correlated with increased er-
lotinib sensitivity (p = 0.22), while MAP17 downregulation
was associated with higher resistance to this tyrosine kin-
ase inhibitor (TKI) (p = 0.13, Fig. 4b). To confirm these re-
sults, we analysed data concerning adenocarcinoma cell
line sensitivity to different EGFR inhibitors from the
GDSC database. We found that high MAP17 expression
correlated with increased sensitivity to six different EGFR
inhibitors: pelitinib (p = 0.16), afatinib (p = 0.02), cetuxi-
mab (p = 0.08), lapatinib (p = 0.32), erlotinib (p < 0.01) and
gefitinib (p < 0.01) (Fig. 4c).
To further support our findings, we assessed the
mRNA expression of MAP17 and EGFR in different
adenocarcinoma PDXs (Fig. 4d, e) and treated them with
erlotinib. Two PDX models with expression of high
levels of wild-type EGFR, TP57 and TP126 were selected
for these experiments. We observed that the model with
low MAP17 expression (TP126) showed no sensitivity to
erlotinib treatment, while the model with high MAP17
levels exhibited sensitivity to this EGFR TKI, with a TGI
rate of 67% (p = 0.048, Fig. 4f ).
Finally, we examined our cohort of patients treated with
erlotinib (Additional file 1: Table S3) and analysed the re-
sponse according to MAP17 levels. When we used the
mean as the cutoff point (Fig. 4g), we found a clear increase
in partial responses, and a small percentage of complete re-
sponses appeared. In total, we observed 50% responders vs
15% in the lowest MAP17 expressors. Furthermore, when
we analysed the 25% patients with tumours expressing the
highest levels of MAP17, we observed 50% responders vs
25% in low-MAP17 expressors (Fig. 4g); however, the
complete responses rate rose to 20%.
Taken together, these data clearly indicate that the
MAP17 level is an independent marker that predicts the
response to erlotinib treatment in lung adenocarcinoma
patients.
MAP17 Expression levels predict efficacy of the
proteasome inhibitor bortezomib in lung adenocarcinoma
Despite our promising findings with platinum-based
therapies and EGFR inhibitors, there is still a high per-
centage of patients who may not respond to these ther-
apies [4, 22], highlighting the necessity for novel
therapies in lung cancer. We previously demonstrated
that the proteasome inhibitor bortezomib shows efficacy
in high-MAP17-expressing malignancies from different
origins, including sarcomas and breast tumours [14, 15].
To study the efficacy of this drug in the context of lung
adenocarcinoma, we determined sensitivity to bortezo-
mib in our lung adenocarcinoma cell line panel (Add-
itional file 1: Tables S4 and S5). We identified a trend
showing that increased MAP17 expression correlated
with higher bortezomib sensitivity (Fig. 5a). To confirm
these results, we studied the sensitivity to bortezomib
and to another proteasome inhibitor, MG132, in adeno-
carcinoma cell lines from the GDSC database, and we
found that high MAP17 expression correlated with
higher sensitivity to both proteasome inhibitors (p =
0.031 and p = 0.078, respectively, Fig. 5b). In addition,
we found that either increased MAP17 mRNA levels in
the H1975 cell line or MAP17 silencing in the
high-MAP17-expressing lung adenocarcinoma Calu-3
cell line both resulted in reduced sensitivity to bortezo-
mib (p = 0.063, p = 0.045, respectively, Fig. 5c).
To assess the efficacy of bortezomib in vivo, we
selected three lung adenocarcinoma PDXs with differ-
ential MAP17 expression levels (TP40, TP57 and TP60,
Fig. 5d). Upon bortezomib treatment, the
high-MAP17-expressing PDX model TP40 showed a
high response to the proteasome inhibitor, while the
medium-MAP17-expressing TP57 model showed a
more modest response, and the low-MAP17-expressing
model TP60 showed no sensitivity to bortezomib
(Fig. 5e), consistent with our in vitro results.
We previously demonstrated that MAP17 prevents cyto-
protective NFκB activation and autophagy induced by bor-
tezomib in both breast and sarcoma tumour cells [14, 15].
Therefore, we next tested whether these molecular markers
might explain the response to bortezomib in our PDX
models (Fig. 5f). The high-MAP17-expressing PDX model
TP40 that responds to bortezomib showed lower levels of
endogenous active NFκB (measured as p65 phosphorylated
at Ser536 and high IKBa), confirming the mechanistic role
of this factor in the bortezomib response. Interestingly,
lower levels of both EGFR activation and its downstream
effector pERK were also observed. This inhibition of the
ERK pathway might contribute to decreased anti-apoptotic
signals, thereby increasing the effect of bortezomib. The ef-
fect on the low-MAP17-expressing model TP60 was the
opposite (Fig. 5f), with high NFKB activation as well as high
EGFR and low autophagy, all signals contributing to block
apoptosis in response to bortezomib treatment. Interest-
ingly, the MAP17-expressing TP57 model with medium ex-
pression of MAP17 showed a partial response to
bortezomib. The TP57 model also exhibited partial activa-
tion of the abovementioned pathways (Fig. 5f). For instance,
under bortezomib treatment, the NFKB levels are de-
creased in the controls, but with the high-expressing
MAP17 TP40 model, these levels increase. Autophagy is
not altered, but MAPK activation is clearly diminished.
Therefore, combined inhibition of NFKb, autophagy
and EGFR protective pathways induced by MAP17
may explain the increase in sensitivity to bortezomib
observed in vivo. The differing activity of each path-
way is very likely molecule- and context-dependent
for each tumour.
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Fig. 5 MAP17 expression predicts sensitivity to bortezomib in lung adenocarcinoma. a Bortezomib sensitivity in low-, medium- and high-MAP17-
expressing lung adenocarcinoma cell lines. b Sensitivity of low- and high-MAP17-expressing adenocarcinoma cell lines to bortezomib and to
another proteasome inhibitor, MG132, obtained from the GDSC database. c Bortezomib sensitivity in the Calu-3 lung adenocarcinoma cell line
after MAP17silencing and in the H1975 lung adenocarcinoma cell line after MAP17 overexpression. d Assessment of MAP17 mRNA expression in
adenocarcinoma PDX models. e Tumour growth assessment (left) and survival analysis (right) in three bortezomib-treated adenocarcinoma PDXs
with differential MAP17 expression. f Western blot showing activation of oncogenic signalling- and autophagy-related pathways in bortezomib-
treated and control adenocarcinoma PDX models
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Discussion
We have shown that MAP17 expression is induced in lung
tumourigenesis, particularly in adenocarcinomas, mainly by
demethylation, and that it correlates with higher tumour
stage. In addition, we provide evidence that MAP17 levels
predict sensitivity to therapies currently under clinical use,
including platinum-based compounds and EGFR inhibitors,
and that treatment with proteasome inhibitors, especially
bortezomib, may be a novel therapeutic approach for
MAP17-overexpressing adenocarcinomas.
MAP17 upregulation is a common feature in tumours
from diverse histological origin, including cervical,
breast, prostate, and ovarian, and is correlated with
tumour progression [7–11, 20, 25]. We show that these
observations may extend to lung carcinomas, which
show increased MAP17 expression compared to that of
normal lung tissue, especially in lung adenocarcinomas,
the histological subtype with the highest MAP17 levels.
Furthermore, we provide evidence that this upregulation
may be a consequence of MAP17 promoter and gene
demethylation. We also observed that MAP17 expres-
sion is higher in tumours with higher stage in two inde-
pendent cohorts. Furthermore, we found a clear
association between MAP17 mRNA levels and worse
prognosis in two independent cohorts, the Lung Meta-
base dataset comprising six different lung cancer cohorts
(1056 samples) and the NCI Directors Challenge Con-
sortium (462 samples). This prognosis extends to tissue
specificity. Therefore, we suggest a prognostic role for
MAP17 expression in NSCLC wherein high levels of
MAP17 indicate poor prognosis in NSCLC.
MAP17 exerts pro-tumourigenic effects in tumour cells
by increasing ROS levels [7]. However, increased ROS may
represent an Achilles’ heel for tumour cells in contexts
where ROS production and apoptosis are over-promoted,
as exposure to platinum-based compounds may be more
effective [26, 27]. Correlating with this hypothesis, high
MAP17 expression is associated with increased survival in
patients treated with cisplatin in several tumour settings
[10, 11]. In line with these results, we provide in vitro, in
vivo and clinical evidence that, in the context of lung
adenocarcinoma, MAP17 levels may be a potential predict-
ive biomarker for platinum-based chemotherapy. There-
fore, determination of expression levels of this gene may
help select patients who will benefit from this type of
therapy.
ROS induction has been related to other treatments,
including EGFR inhibitors [24, 28], so we examined
whether MAP17 expression can predict the response to
EGFR-targeted therapy. We found that high MAP17 ex-
pression correlates with increased sensitivity to a variety
of EGFR inhibitors in vitro and with increased sensitivity
to erlotinib in lung adenocarcinoma PDX models with
high EGFR activation. EGFR inhibitors are the current
standard of care for adenocarcinoma patients with EGFR
activating mutations. However, 10–15% of these patients
do not respond to this therapy, highlighting the necessity
for predictive biomarkers to identify resistant tumours
[29]. Additionally, the EGFR inhibitor erlotinib was
shown to prolong survival in unselected NSCLC patients
after first- or second-line chemotherapy, suggesting that
some wild-type EGFR tumours may be sensitive to
EGFR inhibition [30]. In fact, our assessment of MAP17
levels in erlotinib-treated patients indicates that high
levels of MAP17 are indicative of better response rates
and even complete responses. Therefore, MAP17 assess-
ment could help select patients who may benefit more
so from EGFR inhibition therapy.
Unfortunately, despite demonstration of efficacy and ap-
proval for clinical use of both targeted treatments and im-
munotherapies in the lung adenocarcinoma setting, a
significant number of patients harbour tumours unre-
sponsive to these treatments [4, 5, 29], leaving them with
very limited therapeutic options. The proteasome inhibi-
tor bortezomib, which has been approved by the FDA for
the treatment of multiple myeloma and mantle cell
lymphoma [12, 13], has been shown as a promising treat-
ment for high-MAP17-expressing tumours from different
origins in preclinical studies [14, 15]. In light of these re-
sults, we examined whether these findings may be ex-
tended to lung adenocarcinomas. We found that high
MAP17 levels are linked to bortezomib sensitivity in our
adenocarcinoma cell lines, confirming these results for
bortezomib and an alternative proteasome inhibitor in a
publicly available database. Furthermore, we found that
MAP17 expression predicts bortezomib response in lung
adenocarcinoma PDXs. These results supported the po-
tential efficacy of bortezomib in high-MAP17 expressing
lung adenocarcinomas. These data are similar to those ob-
tained for breast carcinoma and sarcoma [14, 15]. In fact,
analysis of multiple myeloma patients also suggests that
high levels of MAP17 are indicative of a better response
[14, 15]. We previously found that MAP17 overexpression
induces a clear increase in sensitivity to bortezomib in
mammary carcinoma and sarcoma cells, which was repro-
duced both in vitro and in vivo [14, 15, 31, 32]. The
MAP17-dependent increase in sensitivity correlated with
inhibition of the cytoprotective effect induced by nuclear
translocation of phosphorylated NFκB and autophagy in-
duced by bortezomib [14, 15, 31, 32].
Bortezomib-induced NFκB phosphorylation promotes
its translocation to the nucleus and its activity as a tran-
scription factor. NFκB nuclear translocation activates
anti-apoptotic genes and promotes survival [33–35].
High levels of MAP17 reduce NFκB nuclear transloca-
tion in response to bortezomib treatment, reducing its
anti-apoptotic role in tumours. Therefore, the presence
of MAP17 renders tumour cells unable to exploit these
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cytoprotective effects [31, 32]. In contrast, it is generally
thought that autophagy has two opposing functions in
tumour cells in response to chemotherapy-induced stress:
cytoprotection and cytotoxicity [36, 37]. Bortezomib also
induced an initial cytoprotective role by inducing autoph-
agy that was reduced by the presence of MAP17, increas-
ing the cytotoxic response to the drug [31, 32].
Ultimately, high levels of MAP17 could be of prognos-
tic value for predicting treatment response in patients
with diseases clinically treated with bortezomib. Add-
itionally, high MAP17 levels could be used to select pa-
tients with other tumours for which bortezomib is not
currently an indication.
Conclusions
Our results suggest a prognostic role for MAP17 in lung
tumours, with particular relevance in adenocarcinomas.
MAP17 levels may convey predictive potential for
platinum-based therapy and EGFR inhibitor efficacy. Fur-
thermore, we propose bortezomib treatment as a novel ef-
ficacious therapy for adenocarcinomas exhibiting high
MAP17 expression.
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